Alzheimer’s Disease

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry

June 6, 2018

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry Contact: Brendan Monahan Rasky Partners, Inc. 413-537-4063 Boston, Ma (June 1st, 2018) –The size and prominence of the Canadian delegation arriving at BIO 2018 – among the largest international delegation – demonstrates the tremendous success that the government’s record setting investment […]

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

May 22, 2018

WCG expands global clinical research support presence WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company’s new office in Tokyo, Japan. WCG’s expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly […]

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

February 21, 2018

Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company’s AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg strengths. The product is manufactured here in the United States in the company’s recently expanded Brookhaven, New York facility. Annual U.S. sales of Namenda XR® were $929 million, according to […]

Latest Alzheimer’s Flop Raises Doubts About ‘Amyloid Hypothesis’

January 25, 2018

Even after Eli Lilly announced that its experimental Alzheimer’s drug solanezumab had failed in clinical trials in late 2016, it continued investigating its potential in patients at the very earliest stages of the memory-stealing disease. The hope was that if the drug could eliminate soluble amyloid-beta—the protein blamed for the brain plaques that form in […]

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

January 4, 2018

TORONTO and CAMBRIDGE, MA, Jan. 4, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease (AD), PMN310, showed absence of binding to amyloid beta (Aβ) plaque in and around blood vessels in AD […]

Comprehend Systems Appoints New CEO in Response to Surging Demand for Clinical Intelligence Solutions; Enterprise Growth Expert to Scale Company and Expand Partner Ecosystem

November 20, 2017

Redwood City, Calif., November 13, 2017—Comprehend Systems, Inc., the leader in Clinical Intelligence solutions, has named Terry Cunningham CEO.  Cunningham will focus on scaling Comprehend in response to explosive customer demand for solutions that reduce time and risk in clinical trials. Cunningham will also drive expanded partner programs to help sponsors achieve faster, better clinical […]

Bioclinica Acquires MDDX Research & Informatics Combining Advanced Image Management Cloud Technology with Its Scientific and Medical Imaging Leadership

November 7, 2017

Best-in-class solution ensures sponsors and CROs have global access to efficient, accurate, and scalable medical imaging to drive better data and outcomes DOYLESTOWN, Pa., Nov. 6, 2017 – Bioclinica®, the world-leading provider of scientific-enabled Medical Imaging, eHealth, and patient-centric solutions supporting clinical research, today announces it has acquired Silicon Valley-based MDDX Research & Informatics, adding […]

Abbvie, Alector To Develop Novel Treatments For Alzheimer’s Disease

October 26, 2017

AbbVie has collaborated with Alector to develop and commercialize new treatments for Alzheimer’s disease and other neurodegenerative disorders.   Under the deal, the companies will study a portfolio of antibody targets, of which AbbVie will have global development and commercial rights to two targets.   Alector has developed an advanced immuno-neurology technology platform to simultaneously […]